Don't Give Teva 'Eighth Bite' At $235M Patent Trial, GSK Says

By Andrew Karpan ( March 6, 2025, 10:29 PM EST) — GlaxoSmithKline has told a Delaware federal judge that Teva’s request for a new trial in the drugmakers’ decade-long, $235 million “skinny label” patent fight over heart failure medication is an “eighth bite at the same apple.”…

SEO Powered Content & PR Distribution. Get Amplified Today.
PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
Source: https://www.law360.com/ip/articles/2307237?utm_source=rss&utm_medium=rss&utm_campaign=section

Generative Data Intelligence

Don’t Give Teva ‘Eighth Bite’ At $235M Patent Trial, GSK Says

Related articles

Fortress Iron L.P. Digs Into Legal Action Against Digger Specialties for Alleged Patent Infringement

HBO succeeds in GAME OF DÖNER opposition; Haribo loses South Korea dispute; Japan counterfeits rise – news digest

Preparing For Disruptions To Life Sciences Supply Chains – Law360

Dhanush – Nayanthara Copyright Saga Update: No Interim Relief, Yet No Mediation?

Recent articles

Court Grants 3AC Liquidators $1.53 Billion Claim Against FTX Amid Bankruptcy Battle

Israel Unleashes New Doctrine to Smash Threats, Secure Borders

[Podcast] Safety First: How to ensure Safety in Intralogistics

[Podcast] Safety First: How to ensure Safety in Intralogistics